The company will put the funds toward advancing its therapeutic pipeline, including a drug it is studying in genetically defined NSCLC and glioblastoma.
The companies will conduct a Phase III trial of datopotamab deruxtecan following positive results from a Phase I TNBC cohort presented at the meeting.
FoundationOneCDx will also automatically be a companion diagnostic for future BRAF inhibitors approved by the FDA that target specific BRAF mutations.
Tumors in younger individuals exhibited a dysregulated molecular aging phenotype and were associated with hallmarks of premature senescence.
A team led by researchers at the University of Cambridge analyzed more than 160 pre-treatment tumor biopsies to identify features linked to treatment response.
The new drug application contains data from the ZENITH20 trial, demonstrating the drug's activity in NSCLC patients with HER2 exon 20 insertion mutations.
The company will use the funding to support commercialization of its blood-based colorectal cancer detection test and to fuel expansion to other tumor types.
The firm plans to put the funds into developing its GoCAR-T platform therapies, BPX-601 and BPX-603, in certain solid tumors.
The companies inked a collaboration to study the drug combination in advanced solid tumors with elevated expression of ILT2 and ILT4.
The pharma firm is using Caris’ comprehensive molecular profiling to help advance its investigational Porcupine inhibitor, RXC004, in the US.